OR WAIT null SECS
October 22, 2020
JSR Life Sciences has increased its European footprint with a new expanded facility in Switzerland, that will combine the company’s two affiliates in one campus.
EC has granted orphan drug designation to Pharming Group for its treatment of activated phosphoinositide 3-kinase delta syndrome, leniolisib.
The Swiss marketing and distribution partner of Diurnal Group, EffRx Pharmaceuticals, has submitted a MAA for Alkindi to Swissmedic.
Nanoform Finland will be initiating the first human trial of a drug candidate nanoformed using the company’s CESS technology in 2020.
October 21, 2020
Vetter has moved into new headquarters located in Ravensburg, Germany, and plans to continue its long-term investment for corporate development.
October 14, 2020
Shimadzu, has opened a new branch office in Copenhagen, Denmark.
Cambrex has completed the expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.
Oxular has been granted rare pediatric disease and orphan drug designations by the US FDA for its proprietary drug, OXU-003.
The UK's MHRA has joined the Australia-Canada-Singapore-Switzerland (ACSS) Consortium of regulators.
Recent data, from BIA and Clarivate, has revealed that investment in UK biotech continues to be strong.